- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Zeo ScientifiX, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| Di | Zeo ScientifiX, Inc.: ZEO ScientifiX Announces That Unaudited Monthly Sales Surpassed $1.0 million in April 2026, the First Time The Company Has Achieved This Milestone. | 151 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESS Newswire / May 12, 2026 / ZEO ScientifiX (OTCQB:ZEOX) ("ZEO" or the "Company"), a regenerative medicine products company serving physician-run clinics across the United... ► Artikel lesen | |
| 21.04. | Zeo ScientifiX, Inc.: ZEO ScientifiX Surpasses 500 Physicians Trained in Regenerative Medicine Compliance; Monthly Masterclasses Average 70+ Clinicians | 175 | ACCESS Newswire | DAVIE, FL / ACCESS Newswire / April 21, 2026 / ZEO ScientifiX, Inc. (OTCQB:ZEOX) ("ZEO ScientifiX"), a provider of industry-leading clinical education in regenerative medicine innovation, proudly announces... ► Artikel lesen | |
| 21.04. | Zeo ScientifiX, Inc. - 8-K, Current Report | - | SEC Filings | ||
| ZEO SCIENTIFIX Aktie jetzt für 0€ handeln | |||||
| 09.04. | Regen Therapy Partners with Stealth Health to Bring Specialized Telemedicine Services and Longevity Programs to 3,000 Clinics--Powered by an Exclusive Scientific and Biologics Strategic Collaboration with ZEO ScientifiX | 2 | CNW | ||
| 09.04. | Zeo ScientifiX, Inc.: Regen Therapy Partners with Stealth Health to Bring Specialized Telemedicine Services and Longevity Programs to 3,000 Clinics - Powered by an Exclusive Scientific and Biologics Strategic Collaboration with ZEO ScientifiX | 400 | ACCESS Newswire | Regen Therapy's 24,000-practitioner network will unlock a fully integrated care ecosystem - featuring Stealth Health's licensed prescriber team and specialized therapies, Metabolic Code-driven longevity... ► Artikel lesen | |
| 07.04. | Zeo ScientifiX, Inc.: ZEO ScientifiX Selected as Qualified Team Advancing into the XPRIZE Healthspan Semi-Finals Stage | 414 | ACCESS Newswire | DAVIE, FL / ACCESS Newswire / April 7, 2026 / ZEO ScientifiX, Inc. (OTCQB:ZEOX) ("ZEO" or the "Company"), a clinical-stage biotechnology company, today announced its selection as a Qualified Team advancing... ► Artikel lesen | |
| 07.04. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.03. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.03. | Zeo ScientifiX, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 29.01. | Zeo ScientifiX, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 21.01. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.01. | ZEO ScientifiX, Inc.: Cytora Therapeutics, Made Scientific, and Zeo ScientifiX Announce Partnership to Manufacture and Commercialize Cytora's Allogeneic Stem Cell Therapy in the United States | 337 | ACCESS Newswire | Three-Way Collaboration to Bring Innovative Oral Mucosal Stem Cell Therapy with U.S. GMP Manufacturing and Commercialization Infrastructure to Patients Seeking Treatment for Non-healing Diabetic Foot... ► Artikel lesen | |
| 05.01. | Zeo ScientifiX, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.12.25 | Zeo ScientifiX, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 23.10.25 | ZEO ScientifiX, Inc.: ZEO ScientifiX Positioned for New Growth as Florida Opens Stem Cell Market | 458 | ACCESS Newswire | New Florida stem cell law provides ZEO with new pathways to market and sell regenerative therapy products and advance clinical research initiatives FORT LAUDERDALE, FL / ACCESS Newswire / October 23... ► Artikel lesen | |
| 09.07.25 | Zeo ScientifiX, Inc.: ZEO ScientifiX Positions for National Growth as Stem Cell Market Opens in Florida | 633 | ACCESS Newswire | ZEO Launches New Website and Agency Partnerships to Address Expected Biologics Market Demand Following Florida's New Stem Cell Law FORT LAUDERDALE, FL / ACCESS Newswire / July 9, 2025 / ZEO ScientifiX... ► Artikel lesen | |
| 24.06.25 | Zeo ScientifiX, Inc.: ZEO ScientifiX Launches Physician-Focused Masterclass Ahead of Florida's SB-1768 Law Implementation | 334 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESS Newswire / June 24, 2025 / ?ZEO ScientifiX, Inc.?("ZEO" or the "Company") (OTCQB:ZEOX), a clinical-stage biopharmaceutical company pioneering the research and development... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 28,465 | -0,44 % | Qiagen erhöht Dividende und stellt weitere Aktienrückkäufe in Aussicht | DJ Qiagen erhöht Dividende und stellt weitere Aktienrückkäufe in Aussicht
DOW JONES--Die Aktionäre von Qiagen können sich über eine höhere Dividende freuen. Wie es in der Einladung zur Hauptversammlung... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,560 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points... ► Artikel lesen | |
| HCW BIOLOGICS | 1,210 | -0,82 % | HCW Biologics Inc.: HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results | MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 81,09 | -0,06 % | Jefferies raises Apogee Therapeutics stock price target on trial outlook | ||
| PRAXIS PRECISION MEDICINES | 341,89 | -0,20 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| CG ONCOLOGY | 66,93 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen | |
| EVOTEC | 4,618 | -1,74 % | KURSRUTSCH bei Nel ASA und Evotec! KURSCHANCE bei HPQ Silicon! | Steht die Aktie von HPQ Silicon vor einer Neubewertung? Dafür gibt es jedenfalls gute Gründe. Die Hochleistungsbatterien haben erneut überzeugt. Damit könnte für Anwendungen in Drohnen, Verteidigung... ► Artikel lesen | |
| BIONTECH | 76,40 | -2,98 % | HV-Termine: Hauptversammlungen u.a. bei Aixtron, BioNTech, BMW, Dt. Börse, Deutz, Freenet, K+S, Lufthansa, MuM, Rheinmetall | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| COGENT BIOSCIENCES | 32,710 | +0,09 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress | ||
| NUVALENT | 102,40 | +0,10 % | Nuvalent, Inc.: Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results | NDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC
NDA for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC under FDA review... ► Artikel lesen | |
| JADE BIOSCIENCES | 23,355 | 0,00 % | Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update | Interim biomarker-rich Phase 1 data for JADE101 to be featured in an oral session at the 63rd European Renal Association Congress Phase 2 trial of JADE101 in IgA nephropathy patients expected to begin... ► Artikel lesen | |
| RELAY THERAPEUTICS | 12,205 | +0,04 % | H.C. Wainwright is Bullish on Relay Therapeutics, Inc. (RLAY) | ||
| TYRA BIOSCIENCES | 37,070 | +0,08 % | Tyra Biosciences GAAP EPS of -$0.64 | ||
| KYMERA THERAPEUTICS | 82,25 | +0,05 % | Kymera presents KT-621 atopic dermatitis trial data at conferences | ||
| BEAM THERAPEUTICS | 27,945 | +0,05 % | H.C. Wainwright reiterates Beam Therapeutics stock rating at buy |
ZEO SCIENTIFIX INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZEO SCIENTIFIX INC finden Sie auf Wallstreet Online.